Trizepatide 40 MG

Trizepatide 40 is a prescription injectable medication used mainly to treat type 2 diabetes and obesity in higher-dose formulations. It is unique because it activates two gut hormone receptors at the same time: GLP-1 and GIP, which together enhance insulin release, reduce glucagon, slow stomach emptying, and suppress appetite. These combined effects lead to strong blood sugar control and significant weight loss compared with older medications. Tirzepatide is given as a once-weekly subcutaneous injection with gradual dose escalation to reduce side effects. Common side effects include nausea, vomiting, diarrhea, constipation, and reduced appetite, especially early in treatment. It is not insulin, but it improves how the body uses its own insulin more effectively. Tirzepatide should be used under medical supervision, particularly in people with gastrointestinal disease, thyroid conditions or those using other glucose-lowering drugs.
Reconstitute: 40mg Vial with 100 units of Bac water (10,000 mcg/mL) We are basing this off a 1mL Insulin Syringe (100 units) for dosing.”
Dosing Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP-1 and GIP receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Its 5-day half-life allows convenient once-weekly subcutaneous dosing. demonstrate superior glycemic control and weight reduction compared to selective GLP-1 agonists.
Reconstitute: Add 3.0 mL bacteriostatic water → 10.0 mg/mL concentration.
DOSE weekly range: 2.5–15 mg once weekly (gradual 4-week titration steps).